Exchange: NASDAQ·Updated 04:10 PM EDT
News
all
press releases
Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
ICON plc (NASDAQ: ICLR) (ICON), a world-leading clinical research organisation, today releases its ICON Cares 2025 Report which outlines how the company is delivering on its environmental, social and governance (ESG) priorities with cutting-edge clinical innovation to drive both industry-leading...
Business Wire
Insider Selling: Linda Grais Unloads $138K Of Icon Stock
Linda Grais, Director at Icon (NASDAQ:ICLR), executed a substantial insider sell on August 12, according to an SEC filing. What Happened: Grais opted to sell 841 shares of Icon, according to a Form 4 filing with theread more...
Benzinga
Director Of Icon Makes $138K Sale
Making a noteworthy insider sell on August 12, DR JOHN CLIMAX, Director at Icon (NASDAQ:ICLR), is reported in the latest SEC filing. What Happened: CLIMAX opted to sell 841 shares of Icon, according to a Form 4 filingread more...
Benzinga
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
Zacks
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.
Zacks
ICON Announces Pricing of USD 2.15 Billion Notes
ICON plc (NASDAQ: ICLR) (ICON), a world-leading clinical research organization, today announced the pricing by its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the Issuer) of $2.15 billion of senior unsecured notes, consisting of $500 million aggregate principal amount...
Business Wire
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.
Zacks
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?
Zacks
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
Zacks

Advertisement|Remove ads.